Moderna to begin trials for its variant-specific COVID vaccine

Wednesday, 03. March 2021 21:03

Moderna, Inc. announced on Wednesday it is set to kick off Phase 1 clinical trials for its coronavirus vaccine candidate built to prevent the new variant of the virus that was first detected in South Africa.

The biopharmaceutical firm said it has "completed manufacturing of clinical trial material and shipped doses to the National Institutes of Health (NIH)," adding that the trials would be "led and funded" by the National Institute of Allergy and Infectious Diseases (NIAID).

"We look forward to beginning the clinical study of our variant booster and are grateful for the NIH’s continued collaboration to combat this pandemic," Moderna CEO Stephane Bancel said in a statement, claiming that the company remains "committed to making as many updates to our vaccine as necessary until the pandemic is under control."

Related Links: 
Author:
Breaking the News / GA